1. Role of Luteinising Hormone Releasing Hormone (LHRH) Agonists and Hormonal Treatment in the Management of Prostate Cancer 
P. Mongiat-Artus, P. Teillac 
European Urology Supplements 
Volume 4, Issue 5, Pages 4-13 (July 2005)
DOI: /j.eursup
Copyright © 2005 Elsevier B.V. Terms and Conditions

2. Fig. 1
Treatment strategies are dependent on the possibility of cure, but overall, LHRH agonists play an important role in the treatment of PCa.
European Urology Supplements 2005 4, 4-13DOI: ( /j.eursup )
Copyright © 2005 Elsevier B.V. Terms and Conditions

3. Fig. 2
Overall survival was significantly better in patients who received immediate hormonal therapy as compared to deferred therapy [25]. Adapted with permission, © 1999 Massachusetts Medical Society. All rights reserved.
European Urology Supplements 2005 4, 4-13DOI: ( /j.eursup )
Copyright © 2005 Elsevier B.V. Terms and Conditions

4. Fig. 3
Subjective responses achieved by LHRH agonists are equal to those achieved by orchiectomy [58]. LUTS: lower urinary tract symptoms.
European Urology Supplements 2005 4, 4-13DOI: ( /j.eursup )
Copyright © 2005 Elsevier B.V. Terms and Conditions

5. Fig. 4
Almost all patients reach serum testosterone castrate levels of ≤50ng/dL in about 3-4 weeks after the first LHRH agonist injection [59–63].
European Urology Supplements 2005 4, 4-13DOI: ( /j.eursup )
Copyright © 2005 Elsevier B.V. Terms and Conditions